77 results
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
area: Audit, Compensation, and Nominating and Corporate Governance. Also, the Board will leverage feedback from its self-evaluation process, which … benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our arimoclomol expanded access program
424B3
kmeuaf l539p4k5dir
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
ihe8urcdl gtd3p
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
hjjp5bi3u2 2dxl
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
7e9c677
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
l6u1ea7648oj8ghme19
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
ljezs5
10 Nov 21
Prospectus supplement
5:19pm
424B3
zzm 7s96xm
19 Oct 21
Prospectus supplement
9:27am
8-K
EX-99.1
ml5u jycfapb7
19 Oct 21
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
9:24am